Compare Talkspace, Inc. with Similar Stocks
Dashboard
1
With a growth in Operating Profit of 87.46%, the company declared Outstanding results in Dec 25
- The company has declared positive results for the last 9 consecutive quarters
- ROCE(HY) Highest at 6.65%
- NET SALES(Q) Highest at USD 63 MM
- OPERATING PROFIT(Q) Highest at USD 4.65 MM
2
With ROE of 6.66%, it has a fair valuation with a 7.34 Price to Book Value
3
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
USD 859 Million (Small Cap)
110.00
NA
0.00%
-0.79
6.66%
7.34
Revenue and Profits:
Net Sales:
63 Million
(Quarterly Results - Dec 2025)
Net Profit:
5 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
40.55%
0%
40.55%
6 Months
92.13%
0%
92.13%
1 Year
78.75%
0%
78.75%
2 Years
43.7%
0%
43.7%
3 Years
616.18%
0%
616.18%
4 Years
200.0%
0%
200.0%
5 Years
-48.6%
0%
-48.6%
Talkspace, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
60.47%
EBIT Growth (5y)
22.65%
EBIT to Interest (avg)
-19.07
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.96
Sales to Capital Employed (avg)
1.59
Tax Ratio
1.74%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
80.17%
ROCE (avg)
0
ROE (avg)
0.65%
Valuation key factors
Factor
Value
P/E Ratio
110
Industry P/E
Price to Book Value
7.34
EV to EBIT
243.08
EV to EBITDA
127.15
EV to Capital Employed
31.36
EV to Sales
3.35
PEG Ratio
0.19
Dividend Yield
NA
ROCE (Latest)
12.90%
ROE (Latest)
6.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 36 Schemes (20.45%)
Foreign Institutions
Held by 45 Foreign Institutions (4.1%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
63.00
59.40
6.06%
Operating Profit (PBDIT) excl Other Income
4.60
2.90
58.62%
Interest
0.00
0.00
Exceptional Items
-1.50
0.00
Consolidate Net Profit
4.80
3.30
45.45%
Operating Profit Margin (Excl OI)
60.80%
37.00%
2.38%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 6.06% vs 9.39% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 45.45% vs 760.00% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
228.90
187.60
22.01%
Operating Profit (PBDIT) excl Other Income
6.00
-3.60
266.67%
Interest
0.00
0.00
Exceptional Items
-1.50
-0.20
-650.00%
Consolidate Net Profit
7.80
1.10
609.09%
Operating Profit Margin (Excl OI)
13.80%
-24.00%
3.78%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 22.01% vs 25.07% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 609.09% vs 105.73% in Dec 2024
About Talkspace, Inc. 
Talkspace, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






